|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor (TNF) receptor family used as a cellular receptor by virion glycoprotein D (gD) of herpes simplex virus (HSV).
|
15016549 |
2004 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Herpesvirus entry mediator A (HVEM), nectin-1 and nectin-2 are cellular receptors of glycoprotein D (gD) of herpes simplex virus type-2 (HSV-2).
|
28671524 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
However, a vaccine consisting of recombinant glycoprotein D from herpes simplex virus (HSV)-2 and deacylated monophosphoryl lipid A adjuvant has recently shown partial efficacy against clinical disease transmitted from HSV-1 and -2 seronegative women (73-74%).
|
14711338 |
2003 |
|
Herpes Simplex Infections
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HVEM acts as both a receptor for the canonical TNF-related ligands, LIGHT [lymphotoxin-like, exhibits inducible expression, and competes with herpes simplex virus glycoprotein D for HVEM, a receptor expressed on T lymphocytes] and lymphotoxin-α, and as a ligand for the immunoglobulin superfamily proteins BTLA (B and T lymphocyte attenuator) and CD160, a feature distinguishing HVEM from other immune regulatory molecules.
|
22017438 |
2011 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, the defined region on gD of BoHV-1 might be essential in viral entry upon comparison with the prototype virus in herpes simplex virus (Alphaherpesvirinae).
|
31654778 |
2020 |
|
Herpes Simplex Infections
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In adult mice, a single-cycle HSV candidate vaccine deleted in glycoprotein-D (ΔgD-2) that induces ADCC provided complete protection against HSV disease and prevented the establishment of latency.
|
31599942 |
2020 |
|
Herpes Simplex Infections
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In particular, we discuss the findings about LIGHT (homologous to lymphotoxins, inducible expression, competes with herpes simplex virus glycoprotein D for herpes viral entry mediator, a receptor expressed on T lymphocytes) in the pathogenesis of IBD, and the potential mechanisms by which LIGHT induces IBD.
|
15790356 |
2005 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, we found that monoclonal antibodies derived from humans vaccinated with the HVEM binding domain of HSV-1 gD (i) neutralized HSV-1 infection in a cell receptor-specific manner, (ii) mediated ADCC, and (iii) reduced ocular disease in virus-infected mice.<b>IMPORTANCE</b> Herpes simplex virus 1 (HSV-1) causes cold sores and neonatal herpes and is a leading cause of blindness.
|
28701403 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, we evaluated a new adjuvant approach for anticancer immunotherapy using a plasmid vector encoding a soluble form of the IL-10 receptor (pIL-10R). pIL-10R was coadministered to mice with a DNA vaccine encoding the type 16 human papillomavirus (HPV-16) E7 oncoprotein genetically fused with glycoprotein D of herpes simplex virus (HSV) (pgDE7h).
|
30806747 |
2019 |
|
Herpes Simplex Infections
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, we have shown that adenovirus-expressing TNFSF14 [LIGHT (name derived from homologous to lymphotoxins, shows inducible expression, and competes with herpes simplex virus glycoprotein D for herpes virus entry mediator, a receptor expressed by T lymphocytes); Ad-LIGHT] inoculated directly into primary 4T1 tumor, a highly aggressive, spontaneously metastasizing mammary carcinoma, followed by surgical removal of the primary tumor can eradicate established and disseminated metastatic tumor cells in the peripheral tissues.
|
17641063 |
2007 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Induction of conformational changes at the N-terminus of herpes simplex virus glycoprotein D upon binding to HVEM and nectin-1.
|
24314649 |
2014 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Infectious vaccinia virus recombinants that contain the herpes simplex virus type 1 (HSV-1) glycoprotein D gene under control of defined early or late vaccinia virus promoters were constructed.
|
2986288 |
1985 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
LIGHT (homologous to lymphotoxins, exhibiting inducible expression, and competing with herpes simplex virus (HSV) glycoprotein D for herpes virus entry mediator (HVEM), a receptor expressed by T lymphocytes) has been involved in various autoimmune and inflammatory disorders.
|
29952668 |
2018 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
LIGHT [the name of which is derived from 'homologous to lymphotoxins, exhibits inducible expression, competes with herpes simplex virus glycoprotein D for herpes simplex virus entry mediator (HVEM), and expressed by T lymphocytes'], is a member of the tumour necrosis factor superfamily that is involved in various inflammatory diseases.
|
22519595 |
2012 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Mapping sites of herpes simplex virus type 1 glycoprotein D that permit insertions and impact gD and gB receptors usage.
|
28255168 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Our approach towards vaccine development is to focus on blocking virus entry mediated by herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) and to prevent the virus from evading complement and antibody attack by blocking the immune evasion domains on HSV-2 glycoproteins C (gC2) and E (gE2), respectively.
|
30551986 |
2019 |
|
Herpes Simplex Infections
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of LIGHT (LIGHT: homologous to lymphotoxins, indicating inducible expression, and competes with herpes simplex virus glycoprotein D for herpes virus entry mediator [HVEM/TR2]) in MDA-MB-231 human breast cancer cells was observed to suppress tumor growth in vivo.
|
12651068 |
2003 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous studies focused on the herpes simplex virus (HSV) of the Simplexvirus genus, for which both the free gD structure and the gD/nectin-1 complex structure were reported at high resolutions.
|
28542478 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Successful retargeting of herpes simplex virus type 1 (HSV-1) has been achieved using vectors that carry a modified envelope glycoprotein D (gD) engineered to interact directly with novel receptors.
|
20924362 |
2011 |
|
Herpes Simplex Infections
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of herpes simplex virus glycoprotein D receptors nectin-1 and herpes virus entry mediator was assessed by quantitative fluorescence-activated cell sorter and correlated with NV1023 entry and oncolysis.
|
17327376 |
2007 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
The immunodominant epitope, gD (362-370), was identified within the C-terminal region of B virus gD that was highly conserved among 19 B virus clinical isolates but was not present in either herpes simplex virus (HSV)-1 or HSV-2 gD.
|
12195371 |
2002 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
The most recent trial was the Herpevac Trial for Women that used gD2 with monophosphoryl lipid A and alum as adjuvants in herpes simplex virus type 1 (HSV-1) and HSV-2 seronegative women.
|
25138572 |
2014 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
The present study characterizes a therapeutic antitumor vaccine based on the genetic fusion of the Herpes simplex virus-1 (HSV-1) glycoprotein D (gD) with the E7 oncoprotein from HPV-16 (gDE7).
|
28522585 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells.
|
25878105 |
2015 |
|
Herpes Simplex Infections
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These humoral factors can generally be divided into those which, like RANKL, are tumour necrosis family (TNF) superfamily members and those which are not; the former include TNFα lymphotoxin exhibiting inducible expression and competing with herpes simplex virus glycoprotein D for herpesvirus entry mediator, a receptor expressed by T lymphocytes (LIGHT), a proliferation inducing ligand (APRIL) and B cell activating factor (BAFF); the latter include transforming growth factor beta (TGF-β), interleukin-6 (IL-6), IL-8, IL-11, nerve growth factor (NGF), insulin-like growth factor-I (IGF-I) and IGF-II.
|
26578261 |
2016 |